Leadership
Chairman’s Message
From the Chairman
Dear Shareholders,
On behalf of the Board of Directors, I am pleased to present Avalon Pharma’s Annual Report for 2025, a year marked by disciplined progress and continued institutional strengthening.
As the Kingdom advances toward Vision 2030 and beyond, Avalon Pharma remains aligned with national priorities to enhance healthcare localization, strengthen manufacturing capabilities, and build sustainable private-sector champions. The Board views this alignment as both a strategic opportunity and a long-term responsibility.
Throughout the year, the Company continued advancing its evolution toward a more diversified and specialty-oriented pharmaceutical platform. The Board maintained close oversight to ensure that growth initiatives remain grounded in sound governance, financial discipline, effective risk management, and prudent capital allocation.
In a dynamic healthcare environment, resilience and institutional maturity are essential. The structural enhancements embedded across the organization reinforce Avalon Pharma’s ability to scale responsibly while safeguarding long-term shareholder value.
The Board also recognizes the importance of human capital, culture, and governance practices in sustaining performance. Continued progress in these areas strengthens the Company’s foundation for future growth.
Looking ahead, we remain confident in Avalon Pharma’s strategic direction. The Board will continue to provide guidance and oversight to support disciplined expansion, deeper participation in higher-value therapeutic segments, and responsible regional growth, always guided by long-term value creation.
On behalf of the Board, I extend our appreciation to management and employees for their dedication, and to our shareholders and partners for their continued trust.